Document is current
Any future updates will be listed below
-
Authors
Guttman-Yassky, Emma
Nia, John K.
Hashim, Peter W.
Mansouri, Yasaman
Alia, Erisa
Taliercio, Mark
Desai, Parth N.
Lebwohl, Mark G.
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (15-0549)
- License Information
-
More Information
Article History
Received: 2 May 2018
Revised: 23 July 2018
Accepted: 10 August 2018
First Online: 18 August 2018
Compliance with ethical standards
:
: John Nia, Peter Hashim, Yasaman Mansouri, Erisa Alia, Mark Taliercio, and Parth Desai have no conflicts of interest to disclose. Dr. Emma Guttman-Yassky is a board member of Sanofi Aventis, Regeneron, Stiefel/GlaxoSmithKline, MedImmune, Celgene, Anacor, AnaptysBio, Celsus, Dermira, Galderma, Glenmark, Novartis, Pfizer, Vitae and Leo Pharma; has received consultancy fees from Regeneron, Sanofi, MedImmune, Celgene, Stiefel/GlaxoSmithKline, Celsus, BMS, Amgen, Drais, AbbVie, Anacor, AnaptysBio, Dermira, Galderma, Glenmark, LEO Pharma, Novartis, Pfizer, Vitae, Mitsubishi Tanabe and Eli Lilly; and has received research support from Janssen, Regeneron, Celgene, BMS, Novartis, Merck, LEO Pharma and Dermira. Dr. Mark Lebwohl is an employee of Mount Sinai, which receives research funds from Amgen, Anacor Pharmaceuticals Inc, Boehringer Ingelheim, Celgene, Eli Lilly and Company, Janssen Biotech, Kadmon Corporation, LEO Pharmaceuticals, MedImmune, Novartis Pharmaceuticals Corporation, Pfizer, Sun Pharmaceuticals Industries Ltd, and Valeant Pharmaceuticals. The authors did not receive any form of compensation, either directly or indirectly, from any company or agency related to the development, authorship, or publication of this article.
